Hengdong Shengwu key facts
- Developer of agonist antibody drugs intended for tumour targeting.
- Notable investors include Tengye Ventures, Zhongshan Health Base Group, Zhongshan Torch Electronic Industry Fund Management.
- Status: Privately Held (backing).
Who backs Hengdong Shengwu
3- ·Watch Hengdong Shengwu: the Monday email on marks, rounds and moves
Hengdong Shengwu funding rounds
No funding rounds for Hengdong Shengwu are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Hengdong Shengwu investors
3 investors are on record for Hengdong Shengwu, including Tengye Ventures, Zhongshan Health Base Group and Zhongshan Torch Electronic Industry Fund Management.
About Hengdong Shengwu
Developer of agonist antibody drugs intended for tumour targeting. The company offers optimised monoclonal antibodies, bispecific antibody constructs, tumour-targeting mechanisms and agonist activity enhancement technologies, enabling the creation of novel therapeutic candidates for cancer treatment with improved efficacy and intellectual property protection.
- Sector
- Healthcare
- HQ
- Zhongshan, China
- Founded
- 2021
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Hengdong Shengwu doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.